CAS: 191545-24-1

Epieriocalyxin A is a natural diterpenoid compound, which is derived from the plant Isodon eriocalyx, a member of the Lamiaceae family. This compound has garnered interest in the scientific community due to its significant biological activities. Epieriocalyxin A primarily exerts its effects by modulating cellular pathways involved in inflammation and cancer. It has been observed to inhibit the proliferation of certain cancer cell lines and induce apoptosis, suggesting its potential as an anti-cancer agent. Additionally, it exhibits anti-inflammatory properties by interfering with specific signaling molecules and pathways associated with inflammatory processes. The applications of Epieriocalyxin A are primarily focused on biomedical research, particularly in the fields of oncology and inflammation. Researchers are investigating its efficacy in pre-clinical models to better understand its mechanism of action and potential therapeutic benefits. Its natural origin and bioactive properties make it a valuable candidate for drug development programs aimed at treating cancer and chronic inflammatory conditions. However, further studies are needed to fully elucidate its pharmacokinetics, safety, and efficacy in clinical settings.

Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.